Targeting DLL3 in ES-SCLC

CME

Future Applications in ES-SCLC: Targeting DLL3 and Emerging Evidence for T-Cell Engagers

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: November 07, 2024

Expiration: May 06, 2025

Carl M. Gay
Carl M. Gay, MD, PhD

Activity

Progress
1 2
Course Completed

Introduction

In this module, Carl M. Gay, MD, PhD, discusses the currently available evidence for and clinical application of agents targeting delta-like ligand 3 (DLL3) including emerging T-cell engagers in extensive-stage (ES) small-cell lung cancer (SCLC).

The key points discussed in this module are illustrated with thumbnails from the accompanying downloadable PowerPoint slideset, which can be found here or downloaded by clicking any of the slide thumbnails in the module alongside the expert commentary. 

Clinical Care Options plans to measure the educational impact of this activity. Some questions will be asked twice: once at the beginning of the activity, and once again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your individual responses will not be shared. Thank you in advance for helping us assess the impact of this education.

Before continuing with this educational activity, please take a moment to answer the following questions.

How many people with SCLC do you provide care for in a typical month?

Which of the following most accurately describes how T-cell engager therapies targeting DLL3 work in patients with ES-SCLC?

Which of the following outcomes was reported from the phase II trial evaluating tarlatamab in patients with previously treated ES-SCLC?

Which of the following most accurately describes patients with SCLC who may be eligible for a clinical trial evaluating a DLL3-targeting T-cell engager therapy?

For those providing patient care, what is your current preferred therapy for patients with ES-SCLC who have progressive disease after frontline platinum-based chemotherapy?